Navigation Links
China Biologic Products to Participate in the Rodman & Renshaw Annual Global Investment Conference
Date:9/3/2009

TAI'AN, China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that the Company's management team will attend the upcoming Rodman & Renshaw Annual Global Investment Conference.

The date, time and location of China Biologic's presentation at the conference are as follows:

    Date:           Thursday, September 10, 2009
    Time:           12.05 p.m. Eastern Time
    Venue:          Asia Track
                    New York Palace Hotel
                    New York, NY

During the conference, the Company will be available to meet with analysts and portfolio managers. Interested parties and investors who wish to meet with China Biologic's management may contact mwoodson@rodm.com or call (212) 430-1782. Participation in the Rodman & Renshaw Annual Global Investment Conference is by invitation only.

About Rodman & Renshaw, LLC.

Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant capital needs, along with research and sales and trading services to investor clients. Rodman is a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets according to PrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems, Inc.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its products to hospitals and other healthcare facilities in China.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:  http://www.chinabiologic.com

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY office) or
     Mr. Gary Chin
     Tel:   +1-646-213-1909
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes
2. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
3. AOBOs Products Included in Chinas Essential Drug List
4. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
5. China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009
6. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
7. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
8. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
9. China Biologic Products Schedules 2009 Second Quarter Earnings Conference Call
10. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):